ConductScience.org, home

Comparison · NCT00523978-16dca91a

Cryoablation vs Standard Treatment With Drugs Only: Freedom From Major Atrial Fibrillation Events (MAFEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cryoablation vs Standard Treatment With Drugs Only: Freedom From Major Atrial Fibrillation Events (MAFEs). Trial comparisons, record NCT00523978-16dca91a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00523978-16dca91a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9690.930.987wilson
Risk in group 20.9150.8340.958wilson
Risk difference, group 1 minus group 20.0547-0.003730.137newcombe hybrid score
Risk ratio, group 1 over group 21.060.9871.14log
Odds ratio, group 1 over group 22.950.9069.6log
Number needed to treat, for one more participant with the outcome on Cryoablation than on Standard Treatment With Drugs Only18.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CryoablationExperimental group or subjects that were cryoablated with Arctic Front® Cardiac CryoAblation Catheter System, including the FlexCath® Steerable Sheath and Freezor® MAX Cardiac Cryoablation Catheter158163OG000
Group 2Standard Treatment With Drugs OnlyA control group receiving only an Atrial Fibrillation Drug who have not previously failed a AF study drug.7582OG001

Outcome

Type
PRIMARY
Title
Freedom From Major Atrial Fibrillation Events (MAFEs)
Description
Subjects that did not have or were free of MAFEs. MAFEs were serious adverse events categorized as cardiovascular death, myocardial infarction, stroke, or hospitalization for AF recurrence/ablation, flutter ablation, embolic events, heart failure, hemorrhage or anti-arrhythmic drug treatment.
Time frame
12 Months
Population
mITT set included all subjects (82 CS, 163 ES) who were enrolled, randomized, and received treatment.

Source ClinicalTrials.gov

Trial

Title
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
NCT number
NCT00523978
Phases
PHASE3
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Arctic Front® Cryoablation Catheter, Flecainide or Sotalol or Propafenone
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Results first posted
2012-08-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00523978-16dca91a